ARCHIVES

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

More RFPs For Smoking/Health Projects Planned For Release As Subcontracts For Enviro Control

March 14, 1975

In Brief: Jane Henney Sworn In As FDA Commissioner; Six Centers Retain Comprehensive Status

December 18, 1998

Community Based Control Program Taking Final Shape

April 29, 1977

NCAB Member Seeks Broder’s Resignation, Gets No support

June 3, 1994

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

March 28, 2014

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

August 26, 2011